TALEN

TALEN1-vegfd

ID

ZDB-TALEN-170322-2

Name

TALEN1-vegfd

Previous Names

TALEN1-figf

Target

vegfd (1)

Target Sequence 1

5' - CTGGATGAGCTTCTGATGT - 3'

Target Sequence 2

5' - CTCCACAACTTCCAGTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
uq9bh	vegfd

Expression

Gene expression in Wild Types + TALEN1-vegfd

No data available

Phenotype

Phenotype resulting from TALEN1-vegfd

No data available

Phenotype of all Fish created by or utilizing TALEN1-vegfd

Phenotype	Fish	Conditions	Figures
midbrain lymph vessel has fewer parts of type endothelial cell, abnormal	vegfd^uq9bh/uq9bh; nim5Tg; nz101Tg; uq8bhTg	standard conditions	Fig. S7 from Bower et al., 2017
medial facial lymph vessel endothelial cell decreased amount, abnormal	vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
midbrain lymph vessel has fewer parts of type endothelial cell, abnormal	vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. S7 from Bower et al., 2017
lateral facial lymph vessel endothelial cell decreased amount, abnormal	vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
thoracic duct lymph vessel development decreased occurrence, abnormal	flt4^hu4602/+; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 3 from Bower et al., 2017
thoracic duct decreased amount, abnormal	flt4^hu4602/+; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 3 from Bower et al., 2017
medial facial lymph vessel endothelial cell decreased amount, abnormal	vegfc^hu5055/+; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
facial lymphatic vessel lymphangiogenesis decreased occurrence, abnormal	vegfc^hu5055/+; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
lateral facial lymph vessel endothelial cell decreased amount, abnormal	vegfc^hu5055/+; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
lymphangioblast cord decreased amount, abnormal	vegfc^hu5055/+; vegfd^uq9bh/+; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
lymphangioblast cord lymph vessel development decreased occurrence, abnormal	vegfc^hu5055/+; vegfd^uq9bh/+; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
cardiac ventricle lymph vasculature absent, abnormal	vegfc^hu5055/+; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
cardiac ventricle lymph vasculature DsRed expression absent, abnormal	vegfc^hu5055/+; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
medial facial lymph vessel endothelial cell decreased amount, exacerbated	vegfc^hu5055/+; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
lymphangioblast cord decreased amount, abnormal	vegfc^hu5055/+; vegfd^uq9bh/uq9bh; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
lymphangioblast cord lymph vessel development decreased occurrence, abnormal	vegfc^hu5055/+; vegfd^uq9bh/uq9bh; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
cardiac ventricle lymph vasculature absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
cardiac ventricle lymph vasculature DsRed expression absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
medial facial lymph vessel endothelial cell decreased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
facial lymphatic vessel lymphangiogenesis decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
lateral facial lymph vessel endothelial cell decreased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
otolithic lymph vessel endothelial cell decreased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
thoracic duct lymph vessel development decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; y1Tg	standard conditions	Fig. 3 from Bower et al., 2017
lymphangioblast cord lymph vessel development decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
thoracic duct decreased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/+; y1Tg	standard conditions	Fig. 3 from Bower et al., 2017
regenerating tissue Collagen increased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	cold damage: heart	Fig. 6 from Vivien et al., 2019
cardiac muscle cell increased length, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
heart animal organ regeneration arrested, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	cold damage: heart	Fig. 6 from Vivien et al., 2019
cardiac muscle cell increased volume, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
myocardium hyperplastic, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
cardiac ventricle hyperplastic, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
cardiac ventricle increased volume, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
cardiac muscle cell hypertrophic, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
myocardium increased volume, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
cardiac muscle cell increased width, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	standard conditions	Fig. 3 from Vivien et al., 2019
clearance of damaged tissue involved in inflammatory response wound healing decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	cold damage: heart	Fig. 6 from Vivien et al., 2019
myocardium increased volume, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh	cold damage: heart	Fig. 6 from Vivien et al., 2019
midbrain lymph vessel lacks all parts of type endothelial cell, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nim5Tg; nz101Tg; uq8bhTg	standard conditions	Fig. S7 from Bower et al., 2017
cardiac ventricle lymph vasculature absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
bulbus arteriosus lymph vasculature DsRed expression absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
cardiac ventricle lymph vasculature DsRed expression absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
bulbus arteriosus lymph vasculature absent, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg	standard conditions	Fig. 2 from Vivien et al., 2019
facial lymphatic vessel lymphangiogenesis decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
thoracic duct lymph vessel development decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 3 from Bower et al., 2017
thoracic duct endothelial cell decreased amount, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 3 from Bower et al., 2017
otolithic lymph vessel endothelial cell decreased amount, exacerbated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
midbrain lymph vessel lacks all parts of type endothelial cell, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. S7 from Bower et al., 2017
medial facial lymph vessel endothelial cell decreased amount, exacerbated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
lateral facial lymph vessel endothelial cell decreased amount, exacerbated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; nz101Tg; y7Tg	standard conditions	Fig. 1 from Bower et al., 2017
thoracic duct lymph vessel development decreased occurrence, exacerbated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; y1Tg	standard conditions	Fig. 3 from Bower et al., 2017
lymphangioblast cord lymph vessel development decreased occurrence, abnormal	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; y1Tg	standard conditions	Fig. 2 from Bower et al., 2017
thoracic duct decreased amount, exacerbated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; y1Tg	standard conditions	Fig. 3 from Bower et al., 2017
intersegmental artery branchiness, ameliorated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; y1Tg + MO3-flt1	standard conditions	Fig. 6 from Bower et al., 2017
intersegmental artery branchiness, ameliorated	vegfc^{hu5055/hu5055}; vegfd^uq9bh/uq9bh; y1Tg + MO4-dll4	standard conditions	Fig. 6 from Bower et al., 2017

Citations